Search research articles
Contact Us
Filters
Showing results (321-330 of 361) with videos related to
Page
of 37
Sort By:
Prostate Cancer and Prostatic Diseases
|
March 1, 2020
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
Oliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, et al.
Cancer
|
December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials
Georges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
JAMA Oncology
|
March 29, 2019
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
Howard I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
Science Translational Medicine
|
August 16, 2013
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate
Sarah J Nelson, John Kurhanewicz, Daniel B Vigneron, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Susan Halabi, William Kevin Kelly, Hua Ma, et al.
Cancer Research
|
November 9, 2022
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Jonathan Chou, Emily A Egusa, Sinan Wang, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Molecular Oncology
|
February 22, 2025
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer
Marina N Sharifi, Eric Feng, Nicholas R Rydzewski, et al.
Page
of 37
Search research articles
Search
Showing results (321-330 of 361) with videos related to
Sort By:
Page
of 37
Prostate Cancer and Prostatic Diseases
|
March 1, 2020
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
Oliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, et al.
Cancer
|
December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials
Georges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
JAMA Oncology
|
March 29, 2019
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
Howard I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
Science Translational Medicine
|
August 16, 2013
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate
Sarah J Nelson, John Kurhanewicz, Daniel B Vigneron, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Susan Halabi, William Kevin Kelly, Hua Ma, et al.
Cancer Research
|
November 9, 2022
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Jonathan Chou, Emily A Egusa, Sinan Wang, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Molecular Oncology
|
February 22, 2025
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer
Marina N Sharifi, Eric Feng, Nicholas R Rydzewski, et al.
Page
of 37